Clinical management of nonhealing
ulcers requires advanced
materials
that can enhance wound closure rates without relying on the release
of drugs or other growth factors to obviate systemic deleterious side
effects. In our previous work, we synthesized an integrin-binding
cell adhesive MNH2 {Fmoc-FFβAR(K)βA-NH2 consisting of an RGD mimic, [R(K)], with an amide terminus},
MOH {Fmoc-FFβAR(K)βA-OH consisting of an RGD
mimic, [R(K)], with acid terminus}, and MR (Fmoc-FFβARGDβA-NH2 consisting of an RGD peptide, reference) with multifunctional
activity. Here, we reported the synthesis, characterization, and performance
of a reversed derivative, R-MNH2 (Fmoc-FFβA(K)RβA-NH2 consisting of an RGD mimic, [K(R)], with an amide terminus)
of an antimicrobial cell adhesive peptide, MNH2. Both peptides
(MNH2 and R-MNH2) were found to interact with
αvβ3 integrin, as shown by docking studies; however, they
differed in cell adhesive properties, hydrogel formation, and antimicrobial
efficacy. Later, the wound healing ability of a series of RGD/RGD
peptide mimics (MR, R-MNH2, MNH2,
and MOH) was studied in a methicillin-resistant Staphylococcus aureus (MRSA)-infected Balb/c mouse
model. All studied peptides showed cell adhesion and wound healing
properties; however, only the amide-terminal RGD peptide mimic, MNH2, and its reversed derivative, R-MNH2, showed
antimicrobial activity in both in vitro and in vivo studies. Of these, MNH2 showed the highest
integrin-mediated spreading, migration, and proliferation of dermal
cells in vitro as well as in vivo. Therefore, the MNH2 peptide mimic represents a paradigm
shift in the development of dermoconductive strategies to treat chronic
wounds.